Quantum Pharma PLC Administration of NuPharm (4255D)
April 26 2017 - 9:15AM
UK Regulatory
TIDMQP.
RNS Number : 4255D
Quantum Pharma PLC
26 April 2017
For immediate release 26 April 2017
Quantum Pharma Plc
('Quantum' or the 'Group')
Administration of NuPharm
Quantum Pharma Plc (AIM: QP.), the service-led niche
pharmaceutical developer, manufacturer and supplier, announces that
following the cessation of trading at NuPharm Laboratories Limited
('NuPharm') in January, NuPharm was placed into administration
earlier today. In accordance with paragraph (g) of Schedule 2 of
the AIM Rules for Companies, Quantum confirms that Chris Rigg, CEO,
was also a director of NuPharm when it was placed into
administration.
- Ends -
For further information:
Quantum Pharma Plc
Chris Rigg, Chief Executive Tel: +44 (0) 1207 279
Officer 404
Gerard Murray, Chief www.quantumpharmaplc.com
Financial Officer
ir@quantumpharma.co.uk
N+1 Singer
(Nominated Advisor & Broker)
Sandy Fraser / Nick Owen Tel: +44 (0) 20 7496
/ James White 3000
Media enquiries:
Buchanan
Henry Harrison-Topham Tel: +44 (0) 20 7466
5000
quantumpharma@buchanan.uk.com www.buchanan.uk.com
Notes to Editors
Quantum Pharma is a service-led, niche pharmaceutical developer,
manufacturer and supplier to the retail pharmacy, pharmaceutical
wholesale, hospital, homecare and care home markets. Quantum Pharma
operates through three divisions - Specials, Niche Pharmaceuticals
and Medication Adherence - offering a portfolio of innovative and
complementary products and services.
For further information, please visit
www.quantumpharmagroup.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSEAFDMFWSESL
(END) Dow Jones Newswires
April 26, 2017 09:15 ET (13:15 GMT)
Quantum Phar. (LSE:QP.)
Historical Stock Chart
From Apr 2024 to May 2024
Quantum Phar. (LSE:QP.)
Historical Stock Chart
From May 2023 to May 2024